VJHemOnc Podcast cover image

Updates in the treatment of CLL from EHA 2024: BTK and BCL2 inhibitor combinations, BTK degraders, and more

VJHemOnc Podcast

00:00

Exploring novel treatments and potential sequencing strategies for CLL

Exploring the effectiveness and advantages of combining BTK and BCL2 inhibitors, BTK degraders, and addressing different BTK mutations in the treatment of chronic lymphocytic leukemia. The chapter also covers the strategic development of these molecules, long-term follow-up needs, and potential sequencing of drug therapies, along with insights on addressing Richter transformation with CD3, CD20 bi-specific EPCRITAMAM in CLL.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app